公开(公告)号：US20180246098A1

公开(公告)日：2018-08-30

申请号：US15757633

申请日：2016-09-08

申请人： FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

发明人： Jutta PLASSLICK-DEETJEN ,  Janine BUECHEL ,  Sonja STEPPAN ,  Manuel LOPEZ-CABRERA ,  Abelardo AGUILERA ,  Rafael SELGAS

IPC分类号： G01N33/569

CPC分类号： G01N33/56966 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/4742 ,  G01N2333/475 ,  G01N2333/52 ,  G01N2333/705 ,  G01N2333/78 ,  G01N2333/96494 ,  G01N2800/347 ,  G01N2800/52

摘要： The invention relates to the field of diagnosis of epithelial-to-mesenchymal transition (EMT), such as mesothelial-to-mesenchymal transition (MMT), in particular EMT of the peritoneum, which often occurs upon peritoneal dialysis. The invention provides a method and kit based on markers comprising at least one extracellular matrix protein, e.g., collagen 13, collagen 6, and/or keratin 34, at least one protein involved in building and/or restructuring of extracellular matrix, e.g., matrix metalloproteinase 1, at least one protein involved in cell-cell and/or cell-matrix contacts, e.g., cadherin 13 or thrombospondin 1, at least one growth factor, e.g., VEGF, and, optionally, at least one BMP antagonist, e.g., Gremlin 1.

公开(公告)号：US20180231558A1

公开(公告)日：2018-08-16

申请号：US15517697

申请日：2015-10-07

申请人： CORNELL UNIVERSITY

发明人： David C. LYDEN ,  Bruno COSTA DA SILVA

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57438 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/46 ,  G01N2333/70557 ,  G01N2333/70585 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/90245 ,  G01N2333/96494 ,  G01N2800/50

摘要： The present invention is directed to a method for identifying an individual who is at risk for developing metastatic liver disease that involves measuring, in a sample isolated from the individual, exosomal levels of one or more markers of metastatic liver disease. Kits for carrying out this method are also disclosed. The present invention also relates to a method of preventing metastatic liver disease in an individual who are at risk for developing the disease that involves administering one or more inhibitors of liver pre-metastatic niche formation.

公开(公告)号：US20180194844A1

公开(公告)日：2018-07-12

申请号：US15788710

申请日：2017-10-19

申请人： Genentech, Inc.

发明人： Dorothy French

IPC分类号： C07K16/28 ,  A61K39/395 ,  G01N33/574 ,  C12N15/113 ,  A61K39/00

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/531 ,  G01N33/57484 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2333/96494

摘要： Provided herein are biomarkers and therapies for the treatment of pathological conditions, such as cancer, and method of using FGFR3 antagonists. In particular, provided is FGFR3 as a biomarker for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US20180125939A1

公开(公告)日：2018-05-10

申请号：US15542041

申请日：2016-01-07

申请人： LINNANE PHARMA AB

发明人： Catharina SVANBORG ,  Ines AMBITES

IPC分类号： A61K38/20 ,  A61P13/02 ,  A61K31/381 ,  G01N33/68 ,  C12Q1/6883 ,  A61K38/17 ,  G01N33/573

CPC分类号： A61K38/2006 ,  A61K31/381 ,  A61K38/17 ,  A61P13/02 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y304/24023 ,  G01N33/573 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/545 ,  G01N2333/96494 ,  G01N2800/348 ,  G01N2800/50

摘要： A method for treating cystitis, in particular acute cystitis, comprising administering to a patient in need thereof, an effective amount of a reagent selected from the group consisting of IL-1β inhibitors and MMP inhibitors, or proteins selected from ASC or NLRP-3. Diagnostic methods are also described and claimed.

公开(公告)号：US09964542B2

公开(公告)日：2018-05-08

申请号：US15011584

申请日：2016-01-31

申请人： Steven Goodison ,  Charles J. Rosser

发明人： Steven Goodison ,  Charles J. Rosser

IPC分类号： G01N33/574 ,  C12Q1/00 ,  G01N33/68 ,  C12Q1/68 ,  G06F19/18

CPC分类号： G01N33/57407 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/5421 ,  G01N2333/775 ,  G01N2333/8132 ,  G01N2333/916 ,  G01N2333/96494 ,  G01N2800/52 ,  G01N2800/7028 ,  G06F19/18

摘要： Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of bladder cancer in a subject are provided by detecting in a urine sample a combination of biomarkers. In one embodiment of the invention, biomarker panels consisting of individual targets listed in Tables 4 through 10 may be detected. In another embodiment of the invention, multiplex biomarker panels of various composition, but including those biomarkers listed above may be detected.

公开(公告)号：US20180120321A1

公开(公告)日：2018-05-03

申请号：US15796201

申请日：2017-10-27

申请人： The Charlotte Mecklenburg Hospital Authority d/b/a Carolinas HealthCare System

发明人： Jonathan M. Gerber

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57426 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  G01N2333/70596 ,  G01N2333/90203 ,  G01N2333/91148 ,  G01N2333/96494

摘要： The present invention provides methods and compositions for identifying leukemic stem cells.

公开(公告)号：US09791460B2

公开(公告)日：2017-10-17

申请号：US14105891

申请日：2013-12-13

申请人： Industrial Technology Research Institute

发明人： Tzu-Ling Tseng ,  Hung-Yi Li ,  Yen-Peng Li ,  Angelina Huai-Lo Lee ,  Yi-Chen Liu ,  Ping-Fu Cheng ,  Wei-Ya Lin ,  Hong-Zen Yeh

IPC分类号： G01N33/53 ,  G01N33/49 ,  G01N33/50 ,  G01N33/576 ,  G01N33/487 ,  G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/487 ,  G01N33/49 ,  G01N33/50 ,  G01N33/5067 ,  G01N33/53 ,  G01N33/576 ,  G01N2333/70539 ,  G01N2333/96494 ,  G01N2333/9723 ,  G01N2800/085

摘要： Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.

公开(公告)号：US20170269065A1

公开(公告)日：2017-09-21

申请号：US15505489

申请日：2014-08-22

申请人： Biopredic International

发明人： Christiane Guillouzo

IPC分类号： G01N33/50

CPC分类号： G01N33/5067 ,  G01N33/5026 ,  G01N33/5035 ,  G01N2333/96494 ,  G01N2800/08

摘要： In vitro methods and kits for modulating and studying mechanical movement of hepatic bile canaliculi lumen through activation or inhibition of the Rho-kinase molecular regulation pathway. In vitro methods and kits for modulating lumen opening and clearing using matrix metalloproteinases, as well as diagnostic methods based upon the same.

公开(公告)号：US20170233495A1

公开(公告)日：2017-08-17

申请号：US15503447

申请日：2015-08-13

申请人： CALYPSO BIOTECH SA ,  MERCK PATENT GMBH

发明人： YOLANDE CHVATCHKO MISSOTTEN ,  LAURENCE GOFFIN ,  OLIVIER LEGER ,  STEVEN M. DUNN ,  CHRISTINE POWER ,  KINSEY MAUNDRELL

IPC分类号： C07K16/40 ,  G01N33/573

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12Y304/24035 ,  G01N33/573 ,  G01N2333/96494

摘要： The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.

公开(公告)号：US09669111B2

公开(公告)日：2017-06-06

申请号：US14383843

申请日：2013-03-07

申请人： THOMMEN MEDICAL AG

发明人： Matthias Schnabelrauch ,  Lorenz Meinel ,  Falko Schlottig ,  Ralf Wyrwa

IPC分类号： A61K49/00 ,  C12Q1/04 ,  C12Q1/37 ,  G01N33/52 ,  G01N33/68 ,  A23G4/14 ,  A61C19/04 ,  A61B5/145 ,  A61B5/00 ,  A61K9/68

CPC分类号： A61K49/0004 ,  A23G4/14 ,  A61B5/14546 ,  A61B5/4552 ,  A61C19/04 ,  A61C2201/00 ,  A61C2201/002 ,  A61K9/0058 ,  A61K49/0069 ,  C12Q1/04 ,  C12Q1/37 ,  C12Q2304/00 ,  G01N33/528 ,  G01N33/68 ,  G01N33/6893 ,  G01N2333/96494 ,  G01N2800/18

摘要： The document proposes a diagnostic chewing gum for identifying the presence of inflammatory tissues in the mouth, in particular in or adjacent to the mandible, the maxilla, an implant or the teeth of a user, comprising a base material or particles (3) embedded and/or attached to the base material; an element (1, 5-7), like e.g. a releasable flavor molecule, attached to the base material and/or the particles, for the generation of a change in the chewing gum directly detectable by the user; wherein the element (1, 5-7) generates the change upon direct or indirect contact with a marker (4), e.g. a proteolytic enzyme, which is released by inflammatory tissue in response to bacterial mediators.